Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 725.28

+3.0%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/12/2018 2:05:00 AM
	Read Replies (1) of 3559

RG7716 preliminary P2 DME results: gene.com Preclinical antibody characterization: ncbi.nlm.nih.gov Reported data are short of the important details, DME severity at baseline and pts characteristics. Based on (web-forum) OCT improvement reports of 177 microns for L and 200 microns for 6 mg RG, indicate that pts were more severe ones (vision 20/50 or worse, thickness >400 microns). If true, for this pts pools Eylea had +16 letter gains at 12 months (52 weeks) which are numerically better than RG of 14 letters at 24 weeks. It is premature (without more details from P2 and extended treatment options) to make any speculative hypothesis what may actually be true RG7716 value. Will be interesting to listen what will Roche disclose at conference.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next